Clarion | A Life Sciences Consultancy

11 Sep 2018

Clarion continues its fall recruiting tour this week at the Dartmouth College Employer Connections Fair. We look forward to meeting students interested in a career in life sciences strategy consulting! For the full calendar of recruiting events that Clarion will be attending, see the link below. http://glassdoor.com/slink.htm?key=vQMju

Campus Events | Clarion

Campus Events - Find out about Clarion activities at your school!

7 Aug 2018

We are excited to announce that In Vivo published an article written by Clarion’s medical director, Amama Sadiq MD, MPH et al. This thought piece discusses the key challenges and potential solutions associated with drug development and commercialization in non-alcoholic steatohepatitis (NASH). NASH is an emerging therapeutic area that is currently attracting substantial interest and investment from the biopharma space. A silent epidemic of the western world triggered by a surge in obesity and metabolic risk factors, NASH affects upwards of 10-15 million Americans and (along with its precursor form NAFLD) is estimated to cost the U.S. more than $100B annually. With no approved therapies for this deadly condition, the unmet medical need is exceptionally high. To learn more about Clarion’s unique insights on NASH, please read the full article: http://glassdoor.com/slink.htm?key=vQm8M

NASH: Flying The Plane While Building It

Drug development for nonalcoholic steatohepatitis (NASH), a form of liver disease, is a game of incomplete information: pipeline evolution is occurring in parallel with continued efforts to better understand and manage the disease. To date, no therapy for patients with NASH has been approved and consequences of the condition can be severe, including cirrhosis and hepatocellular carcinoma.